Next Article in Journal
Chemoradiotherapy but Not Radiotherapy Alone for Larynx Preservation in T3. Considerations from a German Observational Cohort Study
Next Article in Special Issue
DNA Methylation and Intra-Clonal Heterogeneity: The Chronic Myeloid Leukemia Model
Previous Article in Journal
The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer
Previous Article in Special Issue
Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia
Review

Role of Lysophospholipid Metabolism in Chronic Myelogenous Leukemia Stem Cells

Department of Stem Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan
Academic Editor: Masahiro Kizaki
Cancers 2021, 13(14), 3434; https://doi.org/10.3390/cancers13143434
Received: 10 May 2021 / Revised: 5 July 2021 / Accepted: 7 July 2021 / Published: 8 July 2021
(This article belongs to the Special Issue Molecular Genetics and Treatment of Chronic Myeloid Leukemia)
In this review, I discuss our recent finding that lysophospholipid metabolism is essential for the maintenance of chronic myelogenous leukemia (CML) stem cells. Lysophospholipids have only one fatty acid chain and so are more hydrophilic than phospholipids, allowing them to act as lipid second messengers. We demonstrated that the stem cell quiescence and TKI resistance displayed by CML stem cells in vivo are sustained by the Gdpd3 enzyme involved in lysophospholipid metabolism. At the mechanistic level, Gdpd3 function allows lysophospholipid metabolism to suppress the AKT/mTORC1-mediated cell growth pathway while activating the stemness factors FOXO and β-catenin. Our results thus link lysophospholipid metabolism to CML stemness, and may thereby open up new therapeutic avenues to overcome CML relapse post-TKI therapy.
It is well known that mature chronic myelogenous leukemia (CML) cells proliferate in response to oncogenic BCR–ABL1-dependent signaling, but how CML stem cells are able to survive in an oncogene-independent manner and cause disease relapse has long been elusive. Here, I put into the context of the broader literature our recent finding that lysophospholipid metabolism is essential for the maintenance of CML stem cells. I describe the fundamentals of lysophospholipid metabolism and discuss how one of its key enzymes, Glycerophosphodiester Phosphodiesterase Domain Containing 3 (Gdpd3), is responsible for maintaining the unique characteristics of CML stem cells. I also explore how this knowledge may be exploited to devise novel therapies for CML patients. View Full-Text
Keywords: CML stemness; lysophospholipid; Gdpd3; Foxo3a CML stemness; lysophospholipid; Gdpd3; Foxo3a
Show Figures

Figure 1

MDPI and ACS Style

Naka, K. Role of Lysophospholipid Metabolism in Chronic Myelogenous Leukemia Stem Cells. Cancers 2021, 13, 3434. https://doi.org/10.3390/cancers13143434

AMA Style

Naka K. Role of Lysophospholipid Metabolism in Chronic Myelogenous Leukemia Stem Cells. Cancers. 2021; 13(14):3434. https://doi.org/10.3390/cancers13143434

Chicago/Turabian Style

Naka, Kazuhito. 2021. "Role of Lysophospholipid Metabolism in Chronic Myelogenous Leukemia Stem Cells" Cancers 13, no. 14: 3434. https://doi.org/10.3390/cancers13143434

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop